Australian biomedical technology incubator Proto Axiom has on Monday announced a second round of financing of $5 million, after its initial raise of $10 million last September.
This is the biotechnology firm’s final close on its Series A terms, with new notable investors such as Melbourne-based Churchill Asset Management, Riverlane Capital, and Eucalyptus founder Benny Kleist, Proto Axiom said in a statement.
The firm has also announced that it has invested in University of Sydney spin-out EndoAxiom.